Uses and Administration of Irbesartan in Kenya
Irbesartan is an angiotensin II receptor antagonist. It is used in the management of hypertension including the treatment of renal disease in hypertensive type 2 diabetic patients. Irbesartan is also under investigation in heart failure.
This specific drug formulation contains Hydrochlorothiazide as an added active ingredient. For precautions and Notes about Hydrochlorothiazide, search for “HCTZ” on the the mainstore.
Irbesartan is given by mouth. Following an oral dose the hypotensive effect peaks within 3 to 6 hours and persists for at least 24 hours. The maximum hypotensive effect is achieved within 4 to 6 weeks after initiating therapy.
In hypertension, irbesartan is given in a dose of 150 mg once daily increased, if necessary, to 300 mg once daily. A lower initial dose of 75 mg once daily may be considered in elderly patients in Kenya of over 75 years, for patients with intravascular volume depletion, and for those receiving haemodialysis. Children aged 6 to 12 years with hypertension may be given a dose of 75 mg once daily, increased to 150 mg once daily if necessary.
For the treatment of renal disease in hypertensive type 2 diabetics in Kenya, irbesartan should be given in an initial dose of 150 mg once daily, increased to 300 mg once daily for maintenance.
Adverse Effects of Irbesartan usage in Kenya
Adverse effects of Irbesartan have been reported to be usually mild and transient, and include dizziness, headache, and dose-related orthostatic hypotension. Hypotension may occur particularly in patients with volume depletion (for example those who have received high-dose diuretics). Impaired renal function and, rarely, rash, urticaria, pruritus, angioedema, and raised liver enzyme values may occur. Hyperkalaemia, myalgia, and arthralgia have been reported. Other adverse effects that have been reported with Irbesartan include respiratory-tract disorders, back pain, gastrointestinal disturbances, fatigue, and neutropenia.
There are no reviews yet.